FDA Will Require Class-Wide REMS For Opioids; “Massive” Program Compared To Past Efforts
This article was originally published in The Pink Sheet Daily
Executive Summary
Class-wide REMS will encompass 24 marketed products from 16 different manufacturers; focus on extended-release products.